Promising agents under evaluation for micro-thrombosis secondary to thrombotic thrombocytopenic purpura include, caplacizumab (an inhibitor of the glycoprotein-Ib/IX-Von-Willebrand factor axis), N-acetyl cysteine, recombinant ADAMTS13, and anti-plasmocyte compounds [134]. Here, ADAMTS13 is linked to thrombotic thrombocytopenic purpura.